US-based merchant bank Burrill & Company has made a second closing of its latest healthcare fund at $505m after corporations joined.
The fundraising followed the $2.6bn raised by venture capital firm New Enterprise Associates earlier this year, with more than $700m targeted for life sciences.
Although corporations are known to have joined Burrill’s fund as limited partners, $200m of the total came from Rusnano, a Russia state-backed investment group, according to news provider Fierce Biotech.
Accountants PricewaterhouseCoopers and US trade…
